ArticleBiochemistry2010
From gene delivery to gene silencing: plasmid DNA-transfecting cationic lipid 1,3-dimyristoylamidopropane-2-[bis(2-dimethylaminoethane)] carbamate efficiently promotes small interfering RNA-induced RNA interference.
Article in Biochemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 18 citations in OpenAlex.
- Review
- Current progress in gene delivery technology based on chemical methods and nano-carriers.Theranostics · 2014Review
- Molecular targeting of liposomal nanoparticles to tumor microenvironment.International journal of nanomedicine · 2013Review
- Cystamine-terminated poly(beta-amino ester)s for siRNA delivery to human mesenchymal stem cells and enhancement of osteogenic differentiation.Biomaterials · 2012Article
- Poly(alkylene oxide) copolymers for nucleic acid delivery.Accounts of chemical research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The cationic lipid 1,3-dimyristoylamidopropane-2-[bis(2-dimethylaminoethane)] carbamate (1,3lb2) was applied as a delivery system for small interfering RNA (siRNA) to inhibit the production of vascular endothelial growth factor (VEGF) in vitro in human prostate carcinoma cell line PC-3. VEGF protein silencing peaked at 94% when cationic lipid-nucleic acid complexes (lipoplexes) were formulated at a nitrogen:phosphorothioate ratio (N:P) of 2 with a dose concentration of 53.7 nM, and the performance of these lipoplexes was not impeded by serum. Knockdown efficiency was maintained for at least 72 h, and an IC(50) of 12 nM lasted for 48 h. Only 20% of the total siRNA became cell-associated at this N:P, at a rate of 25 ng/h. Lipoplexes of the optimal formulation were relatively monodisperse, having an average diameter of 634 nm and a zeta potential of -21.3 mV. Formation of the 1,3lb2-siRNA complex reached 94% at an N:P of 2 and was positively cooperative; the binding constant was calculated in the range of 10(5) M(-1), and a Hill coefficient of 3 was determined. 1,3lb2 was found to be a nontoxic and potent carrier of siRNA that binds to the nucleic acid effectively and whose lipoplexes promote long-lasting inhibition, have high biological activity at low N:Ps, and are functional in the presence of serum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.